- The US FDA approved KLOXXADOTM (Nasal Spray, 8mg) for the emergency treatment of opioid overdose observed in respiratory and/or CNS depression in adult and pediatric patients.
- In a survey, Narcan (Nasal Spray, 4mg) showed 34% attempted reversals used two or more doses. A separate study published in 2019 showed that the percent of overdose-related emergencies in the US requiring multiple doses of naloxone during 2013-2016 increased to 21% which represented a 43% increase over 4 years
- KLOXXADOTM contains double the amount of naloxone per spray as Narcan in a ready-to-use nasal spray and it is expected to be available in H2’ 21
Click here to read full press release/ article | Ref: PRNewswire | Image: Hikma